BCL2 expression was also a significant prognostic indicator in subgroups including tumor size > 2 cm, stage II, ER-positive, HER2-negative, histologic grade 1 or 2, positive lymphovascular invasion, and body mass index ≤ 25 kg/m2. The gene discussed is ERBB2; the disease is neoplasm.